102 related articles for article (PubMed ID: 2116500)
1. Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.
Bruntsch U; de Mulder PH; ten Bokkel Huinink WW; Clavel M; Drozd A; Kaye SB; Renard J; van Glabbeke M
J Biol Response Mod; 1990 Jun; 9(3):335-8. PubMed ID: 2116500
[TBL] [Abstract][Full Text] [Related]
2. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma.
Quesada JR; Kurzrock R; Sherwin SA; Gutterman JU
J Biol Response Mod; 1987 Feb; 6(1):20-7. PubMed ID: 3104544
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
Rinehart JJ; Malspeis L; Young D; Neidhart JA
J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
[TBL] [Abstract][Full Text] [Related]
4. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
Kuzmits R; Scheithauer W; Ludwig H; Flener R
Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of i.v. administered recombinant gamma interferon in cancer patients.
Kurzrock R; Quesada JR; Rosenblum MG; Sherwin SA; Gutterman JU
Cancer Treat Rep; 1986 Dec; 70(12):1357-64. PubMed ID: 3098417
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
[TBL] [Abstract][Full Text] [Related]
7. Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Results of a phase II trial.
Otto U; Conrad S; Schneider AW; Klosterhalfen H
Arzneimittelforschung; 1988 Nov; 38(11):1658-60. PubMed ID: 3145743
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and pharmacokinetics of continuous subcutaneous infusion of low-dose interferon-gamma: a pilot study.
Satake I; Tari K; Nakagomi K; Ozawa K
Jpn J Clin Oncol; 1993 Dec; 23(6):356-62. PubMed ID: 8283789
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
13. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
14. [Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].
Jacqmin D; Bergerat JP; Dufour P; Bollack C; Prévot G; Jurascheck F; Bailly G; Degaris S; Oberling F
J Urol (Paris); 1987; 93(8):463-6. PubMed ID: 3440838
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.
Ellerhorst JA; Sella A; Amato RJ; Tu SM; Millikan RE; Finn LD; Banks M; Logothetis CJ
Cancer; 1997 Dec; 80(11):2128-32. PubMed ID: 9392335
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
17. Multi-cytokine therapy for advanced renal cell carcinoma: determination of the minimal effective dose.
Hamada I; Kato M; Okada K
Anticancer Res; 2002; 22(4):2429-36. PubMed ID: 12174939
[TBL] [Abstract][Full Text] [Related]
18. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.
Small EJ; Weiss GR; Malik UK; Walther PJ; Johnson D; Wilding G; Kuzel T; Bajamonde A; Paton V
Cancer J Sci Am; 1998; 4(3):162-7. PubMed ID: 9612597
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma.
Creagan ET; Ahmann DL; Long HJ; Frytak S; Sherwin SA; Chang MN
Cancer Treat Rep; 1987 Sep; 71(9):843-4. PubMed ID: 3113730
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of recombinant interferon alpha-C in patients with metastatic renal cell carcinoma.
Merimsky O; Inbar M; Merimsky E; Kovner F; Spitzer E; Laufer R; Braf Z; Chaitchik S
Mol Biother; 1990 Sep; 2(3):155-9. PubMed ID: 2222899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
